每经AI快讯，海昌海洋公园(02255.HK)反弹逾5%，截至发稿，涨5.68%，报0.465港元，成交额2219.46 万港元。 ...

Core Viewpoint - Peijia Medical-B (09996.HK) experienced a significant increase in stock price, rising nearly 7% to 6.21 HKD with a trading volume of 7.4878 million HKD [1] Summary by Category - **Stock Performance** - The stock price of Peijia Medical-B rose by 6.88% to reach 6.21 HKD [1] - The trading volume was reported at 7.4878 million HKD [1]

每经AI快讯，卓悦控股(00653.HK)午前涨超26%，截至发稿，涨26.56%，报0.081港元，成交额370.83万 港元。 ...

同源康医药-B（02410）早盘涨超5%，截至发稿， 股价上涨5.21%，现报13.54港元，成交额2597.09万 港元。 在今年9月份的世界肺癌大会上，同源康医药发布的艾多替尼片针对非小细胞肺癌脑转移关键Ⅱ期临床 试验引起同行高度关注。据悉，艾多替尼片（TY-9591）是同源康医药针对EGFR经典突变开发的高选 择性小分子抑制剂，公司已于2024年11月完成附条件批准上市资格的224例患者入组，并已于2025年4月 提交预上市（Pre-NDA）申请，预计2025年4季度正式提交附条件上市申请。 公司在中期业绩会上表示，目前正在准备TY-9591附条件上市NDA申请，将其用于表皮生长因子受体 （EGFR）突变肺癌脑转移的一线治疗，以及正在中国进行TY-9591单药治疗的注册性III期临床试验， 将其用于EGFRL858R突变的局部晚期（IIIb至IV期）或转移性NSCLC的一线治疗。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 同源康医药-B（02410）早盘涨超5%，截至发稿， 股价上涨5.21%，现 ...

Core Viewpoint - The Hong Kong restaurant sector showed active performance with significant gains in various stocks following the Central Economic Work Conference, which emphasized domestic demand and consumer spending recovery [1][2]. Group 1: Market Performance - Shanghai Xiaonan Guo increased by over 7% [2] - Jiumaojiu rose nearly 5% [2] - Other notable gains included Yum China, Nayuki Tea, and Haidilao, each rising close to 3% [1][2] - Xiabuxiabu saw a 2.5% increase, while Xiaocaiyuan and Hite International also experienced upward movement [1] Group 2: Policy Implications - The Central Economic Work Conference, held on December 10-11, outlined key policies aimed at boosting domestic consumption and addressing income growth for urban and rural residents [1] - The meeting's positive signals are expected to facilitate the ongoing recovery of restaurant consumption, benefiting the sector as the overall consumer environment shows signs of gradual improvement [1] - Analysts from Galaxy Securities highlighted the importance of focusing on the medium to long-term consumption goals outlined in the 14th Five-Year Plan, with a short-term focus on specific policies related to consumption expected to be implemented by 2026 [1]

摩根大通发表报告指，预期网易明年仍有更多上行空间，主要受多款新游戏驱动，并将其列为中国数码 娱乐板块的首选股，美股和港股目标价分别为190美元和295港元，评级"增持"。该行目前预测明年在线 游戏收入年增15%。《燕云十六声》国际市场的成功，对网易以及中国游戏开发商而言都是一座重要里 程碑，有利未来其他面向国际市场的3A大作如《ANANTA》。 同时，该行认为网易很有可能在明年纳 入港股通，目前网易估值明显低于中国主要游戏同业，一旦纳入港股通，预期将触发进一步估值重评。 ...

12月12日，上交所发布关于中国能源建设股份有限公司2025年面向专业投资者公开发行科技创新可续期 公司债券（第一期）（品种一）上市的公告。 来源：市场资讯 依据《上海证券交易所公司债券上市规则》等规定，上交所同意中国能源建设股份有限公司2025年面向 专业投资者公开发行科技创新可续期公司债券（第一期）（品种一）于2025年12月15日起在上交所上 市，并采取匹配成交、点击成交、询价成交、竞买成交、协商成交交易方式。该债券证券简称为"能建 YK07"，证券代码为"244323"。 ...

卓悦控股(00653)午前涨超26%，截至发稿，涨26.56%，报0.081港元，成交额370.83万港元。 业务授权合作：集团有意将部分产品及设备授权紫元元在大湾区区域的销售权利，紫元元发挥在中国内 地多年网格布局的销售优势，推动产品及设备的市场布局，达成双方共赢。 消息面上，12月11日，卓悦控股发布公告，公司附属公司卓悦供应链管理有限公司与紫元元控股集团有 限公司(08223)于2025年12月11日，就有关集团可能与紫元元达成的战略合作计划订立不具法律约束力 的谅解备忘录，代表协议双方的初步共识，而可能合作须待协议双方订立正式合作协议方告落实。 优势互补的合作：利用集团在美妆零售行业的领军优势、紫元元在全中国范围内的运营经验及销售资 源，各方将探索在市场开拓、产品合作、设备支援以及人才交流等领域的合作，积极探索互惠互利的业 务合作模式。 大湾区区域合作探索：紫元元与卓悦供应链管理有限公司有意成立合资公司，发挥双方各自优势，在大 湾区范围内共同建立线上及线下"跨境新零售"，开启跨境新零售业务模式。 公告称，集团与紫元元将在跨境新零售务领域密切合作，包括以下内容： ...

Core Viewpoint - Peijia Medical-B (09996) shares rose nearly 7%, currently up 6.88% at HKD 6.21, with a trading volume of HKD 7.4878 million [1] Group 1: Company Developments - Peijia Medical announced that on December 11, it received approval from the National Medical Products Administration of the People's Republic of China for the registration application of the TaurusTrio Transcatheter Aortic Valve (TAV) system [1] - The TaurusTrio TAV system is developed and manufactured by the company under an exclusive license obtained from JenaValve Technology, Inc. for the Trilogy Transcatheter Heart Valve (THV) system [1] - The Trilogy THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial surgeries in real-world clinical practice as of the announcement date [1] Group 2: Market Implications - The company anticipates that the successful launch of the TaurusTrio TAV system in China will provide a safe and effective treatment option for patients with severe aortic regurgitation (AR), addressing a significant unmet clinical need [1]

Core Viewpoint - Peijia Medical-B (09996) experienced a nearly 7% increase in stock price following the approval of its TaurusTrio™ transcatheter aortic valve (TAV) system by the National Medical Products Administration of China [1] Group 1: Company Developments - Peijia Medical announced the approval of its TaurusTrio™ TAV system's registration application on December 11 [1] - The TaurusTrio™ TAV system is developed and manufactured based on an exclusive license from JenaValve Technology, Inc. for the Trilogy™ transcatheter heart valve (THV) system [1] - The Trilogy™ THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial surgeries in real-world clinical practice as of the announcement date [1] Group 2: Market Implications - The company anticipates that the successful launch of the TaurusTrio™ TAV system in China will provide a safe and effective treatment option for patients with severe aortic regurgitation (AR), addressing a significant unmet clinical need [1]